Quenching the Fire of Inflammation
Ziltivekimab targets IL-6, the hidden killer that drives plaque buildup. This antibody 'quenches the fire' in blood vessels to reduce heart attacks where cholesterol is already low.
Strategic Data Expansion 2026.4
Immunometabolism
Targeting high CRP levels to reduce heart risk. LSI keywords like 'IL-6 inhibition' and 'residual inflammatory risk' are now standard.
Residual Risk Mitigation
Inflammatory Reduction
$$R_i = \int (1 - ext{hsCRP}_{post}) \, dt$$
Strategic Advice: Ask for an hs-CRP test to see if inflammation is your primary heart risk.